Investors Urged to Participate in Ultragenyx Securities Fraud Lawsuit for Potential Compensation
Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit Overview
In a significant development for investors, the Rosen Law Firm has announced that it is advising shareholders of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) regarding a potential securities fraud lawsuit. The firm is specifically focusing on individuals who purchased Ultragenyx common stock during the period from August 3, 2023, to December 26, 2025. This period, designated as the
Topics Other）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.